About Arg1-d

This author has not yet filled in any details.
So far Arg1-d has created 19 blog entries.

KOL and Patient Caregiver Webinar on Arginase 1 Deficiency

By |2022-02-18T10:17:29-08:00February 18th, 2022|

PEGZILARGINASE Trial Discussion. Amazing presentation with Dr. Diaz, Dr. Burton and our own Tanja Brandt discuss Arginase 1 Deficiency, the Phase 2 and Phase 3 trial. Tanja discusses the day to day care taking of an individual with Arg1D. Great information on Arginase Deficiency 1 and the future of treating with the enzyme. This link [...]

Phase 3 PEACE study achieved its primary endpoint

By |2021-12-09T14:06:09-08:00December 9th, 2021|

I am excited to share with you that today we announced our Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) study achieved its primary endpoint with a statistically significant reduction in plasma arginine levels. Pronounced and sustained plasma arginine reduction was accompanied by a positive trend in the Gross Motor Function Measure Part E (GMFM-E), a key clinical assessment of patient mobility. Based on these [...]

A Song for Jackson

By |2021-11-29T11:39:26-08:00November 19th, 2021|

A Song for Jackson This song is dedicated to Jean, my partner, our son Jackson, the children and families affected by Arginase 1 Deficiency, Urea Cycle Defects, and rare diseases. My name is Leafy Wilson. In May of 2017, I started writing this song about the experience shared with my partner Jean, our son [...]

Meet Jackson

By |2021-10-28T10:29:51-07:00October 28th, 2021|

Meet Jackson Meet Jackson, age 30, with parents Jean and Leafy Southern California Living with ARG1-D Jackson, age 30, is a self-described cooking fanatic. It is a joyful family experience, involving his mom Jean and stepmom Leafy, bringing this already close-knit family even closer together. “I love to make Thanksgiving dinner, with all the [...]

Meet Nina

By |2021-10-22T10:28:33-07:00October 21st, 2021|

Meet Nina Meet Nina At seven years old, Nina has never met a stranger – each person she meets is immediately her friend.  Nina loves to paint, to create and would do arts and crafts all day if her parents would let her. “Nina simply has a way of making others feel good,” her [...]

Listening Session Report

By |2022-03-23T09:42:13-07:00October 11th, 2021|

FDA Family-Led Listening Session Report On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals with officials [...]

Meet Willow

By |2021-10-11T14:25:55-07:00October 11th, 2021|

Meet Willow Since the moment her mom Tanja realized she was pregnant, her daughter Willow has been full of surprises. Today, Willow is a nurturing, kind, sweet 10-year-old, who loves her new dog Teddy. She is also thoughtful, strong-willed, and stubborn – qualities she needs as she lives with Arginase 1 Deficiency (ARG1-D). Willow [...]

Aeglea BioTherapeutics & Immedica Commercialization Agreement

By |2021-08-25T16:13:41-07:00August 25th, 2021|

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East Published: Mar 22, 2021 Original Story HERE AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative [...]

Aeglea BioTherapeutics Launches THINK ARGININE™

By |2021-08-25T16:03:27-07:00August 25th, 2021|

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency 05/06/2021 Original Story HERE Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human [...]

Go to Top